MedTrace Logo

Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects

NCT02146625 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-12-29

No results posted yet for this study

Summary

The objectives of this study are:

* To evaluate the safety and tolerability of CJ-40002 after single SC injection in healthy male volunteers.
* To evaluate the PK of CJ-40002 after single SC injection in healthy male volunteers.
* To evaluate the PD of CJ-40002 after single SC injection in healthy male volunteers.
* To evaluate the ADA of CJ-40002 after single SC injection in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

CJ-40002

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Min Soo Park, MD, PhD · Yonsei University College of Medicine, Seoul, Korea

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-03-31
Completion
2015-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146625 on ClinicalTrials.gov